2018 Top Chinese Clinical Investigators

2018 Top Chinese Clinical Investigators

In recent years, we have seen more and more original oncology publications from top researchers in China. Those cutting-edge findings are not only practice-changing in China, but also have worldwide influence and impact and are well-recognized by academic societies. Some of the research was initiated by original molecules from China; some of them were inspired by new treatment combinations.

After a careful tally of votes from over 120K physicians and peer KOL evaluation, we are thrilled to present the 2018 Top 10 Chinese Clinical Investigators.

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

Prof. Ruihua Xu
Sun Yat-sen University Cancer Center
Video Link: Watch Video

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

Prof. Binghe Xu
Cancer Hospital Chinese Academy of Medical Sciences

Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acidfor non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial

Prof. Xiaojun Huang
Institute Of Hematology, Peking University/Peking University People’s Hospital

Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study

Prof. Xin Huang
Sun Yat-sen University Cancer Center
Video Link: Watch Video

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

Prof. Yilong Wu
Guangdong Provincial People’s Hospital
Video Link: Watch Video

Camrelizumab (SHR-1210) alone or in combination with gemcitabine pluscisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Prof. Li Zhang
Sun Yat-sen University Cancer Center
Video Link: Watch Video

Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells

Bo Zhu, PhD
Xinqiao Hospital, Third Military Medical University (Chongqing, China)

Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer

Prof. Zefei Jiang
307 Hospital of the Chinese People's Liberation Army
Video Link: Watch Video

A Randomized Multicentered Phase 2 Study to Evaluate SHR-1210 (PD- 1 Antibody) in Subjects with Advanced Hepatocellular Carcinoma (HCC) who Failed or Intolerable to Prior Systemic Treatment

Prof. Shukui Qin
People’s Liberation Army (PLA) 81 Hospital (Nanjing, China)
Video Link: Watch Video

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Prof. Chengcheng Fu
The First Affiliated Hospital of Soochow University
Video Link: Watch Video

Brought to you by